Second Genome: Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders
Patent advances lead mucosal healing program candidate, with potential application in multiple gastrointestinal disorders
Read full article »
Second Genome is a clinical-stage pharmaceutical company that focuses on developing microbiome-based therapeutics for the treatment of chronical diseases and illness.
Read more